Lung PD-L1 AI Brochure
Learn more about the automated workflow and benefits of utilizing Lung PD-L1 AI.
Lung PD-L1 AI Brochure Read More »
HALO Clinical AI
HALO Clinical AI Flyer
Check out our flyer to learn more about HALO Clinical AI Solutions
HALO Clinical AI Flyer Read More »
Clinical Scoring and Validation of a Comprehensive AI-powered Tumour Content and Lung Macrodissection Algorithm
Learn more about Lung Macrodissect AI, an AI-based tool for tumor content quantification and ROI selection guidance.
Validation and Clinical Implementation of Breast IHC AI
Learn how Kaiser Permanente deployed Breast IHC AI as a laboratory developed test.
Validation and Clinical Implementation of Breast IHC AI Read More »
HALO AP Integrations
Read this white paper to learn about the importance of integration and interoperability in digital pathology and explore examples of how flexible solutions like HALO AP® can enhance workflow efficiency and diagnostic accuracy.
HALO AP Integrations Read More »
Automated PD-L1 Tumor Proportion Scoring Algorithm in Non-Small Cell Lung Cancer for Multiple Companion Diagnostic Assays
Read about the development and validation of an AI-based PD-L1 scoring algorithm for HALO AP®.
Development & Validation of an AI-based Tumour Cell Estimation Algorithm for Use in a Lung Adenocarcinoma Molecular Pathology Workflow
Learn more about the development and validation of an AI-based molecular pathology algorithm for estimating tumour cells in lung adenocarcinoma.
Development & Validation of an AI-based Workflow for Clinical Scoring of HER2, ER, PR, & Ki67 Immunohistochemistry in Breast Cancer Tissue
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI
Albuquerque, NM, April 17, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today the expansion of their macrodissection suite with the launch of CRC Macrodissect AI. This expanded portfolio of AI powered tools by Indica Labs will facilitate a macrodissection workflow that minimizes human error and improves efficiency across multiple disease sites. Utilizing the integrative power of artificial intelligence and digital pathology, CRC Macrodissect AI will advance the field of molecular pathology and offer unparalleled insight into colorectal carcinoma.
Indica Labs Expands their Macrodissection Suite with the Launch of CRC Macrodissect AI Read More »